As part of a reorganization, Sandoz is eliminating 104 jobs in the US, specifically from its New Jersey operations that are engaged in development and commercial activities, according to a spokeswoman, who confirmed some details from a state notice about the job cuts.
The cuts amount to 5 percent of the US workforce, which currently numbers more than 2,000, according to the spokeswoman for Novartis (NVS), which owns the Sandoz generic drugmaker. About 24,000 people work for Sandoz worldwide.
The spokeswoman says Sandoz is transferring some development work from its East Hanover, New Jersey, site to other locations, while also streamlining North American commercial operations. "We believe these changes will make us more competitive, and have identified several areas where we will simplify and reinvest, with a focus on strengthening the organization,” she says.
This is only the latest example of ongoing cutbacks in the pharmaceutical industry, notably among big brand-name drugmakers that have been grappling with patent expirations on big sellers and face generic competition. Novartis (NVS), for instance, announced plans earlier this year to eliminate 2,000 jobs in the US (back story).
5 Comments
Labor department doesn't know? Illegal to even ask?
Yes, the notice indicates 84, but the spokesperson provided a larger tally when I wrote with some questions.
Cheers ed